Pharmacy Times November 20, 2024
Key Takeaways
- Alzheimer’s disease disproportionately affects older adults, women, and racial and ethnic minorities, highlighting the need for equitable treatment outcomes.
- The study analyzed treatment benefits and costs across diverse subgroups, revealing minor differences in cost-effectiveness and QALY gains.
- Diagnostic advancements, such as blood-based biomarkers, could significantly enhance the impact of AD treatment.
- Limitations include subgroup variability and challenges in assessing health equity, emphasizing the need for targeted policies to reduce disparities.
Policies that focus on earlier diagnosis, treatment initiation, and expanded access to treatment can further improve treatment and health equity impacts.
Alzheimer disease (AD) disproportionately affects older adults, women, racial and ethnic minority groups, and individual with lower socioeconomic and educational levels. Because these...
Today's Sponsors
Today's Sponsor